Parkinson's disease (PD) is a common neurodegenerative disorder characterized by dopaminergic neuronal loss in the substantia nigra and other brain areas. Despite the vast majority of cases being sporadic, at least six genes have been identified so far that are responsible for autosomal dominant or recessive forms of parkinsonism. The PARK6 locus was mapped to chromosome 1p36 in a Sicilian consanguineous family with autosomal recessive early-onset parkinsonism, and subsequent linkage analysis in other two consanguineous families, from central Italy and Spain, allowed mapping of the gene to a 2.8cM region on chromosome 1p35-36. Sequencing analysis of candidate genes within the region led to the identification of homozygous mutations in the phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1) gene: both Italian families carried the W437X non-sense mutation, while the Spanish family carried the G309D missense change. 
the third or fourth decade (about 65% of cases for whom age at onset is available), with a mean age at onset of 32.4 years (standard deviation
[SD] 11.8). However, patients have been reported with onset in the first to second decades as well as the seventh decade of life (range: nine to 67 years). 9, 14, 18, 21, [34] [35] [36] Despite these occasional reports, patients with onset above 50 years of age are rare and nearly invariably found among relatives of early-onset probands. 11, 14, 21, 24 Progression is generally slow, and many patients maintain relatively low Unified Parkinson's Disease
Rating Scale (UPDRS) III motor scores and preserved functional and working abilities after many years of disease. Response to dopaminergic treatment is good or excellent in most cases, and tends to persist for many years, although drug-related dyskinesias and fluctuations of symptoms often occur early. Only one PINK1 homozygous patient has been described who underwent surgery for bilateral subthalamic nucleus deep brain stimulation (DBS). In this patient, a 60-year-old woman with onset of disease at 31 years of age, DBS produced a substantial benefit, with ~45% reduction of the UPDRSIII off score, which persisted over time. 37 The mean age at onset of PINK1 heterozygotes is 49.0 years (SD: 12.3; range 13-73), about 15 years older than that of PINK1 bi-allelic carriers, and about 60% of cases had onset in the fifth or sixth decade of life.
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Clinical Features
With the already mentioned exceptions of earlier age at onset (<50 years), slower disease progression, and better response to levodopa, ARP due to PINK1 bi-allelic mutations is overall similar to idiopathic PD.
On average, patients appear to have a more frequent onset in a lower limb and higher occurrence of akinetic-rigid presentation, gait impairment, urinary urgency, and early drug-induced dyskinesias. 10, 17 Atypical features at onset, such as dystonia and diurnal fluctuations, have been reported in fewer than one-quarter of PINK1 bi-allelic mutation carriers, mostly with very early onset. 8, 10, 35, 38 In these cases, PINK1-related parkinsonism can even resemble Dopa-responsive dystonia, and the two conditions need to be considered in differential diagnosis. 35 Other peculiar features that have been described include hyper-reflexia 11 and restless leg syndrome. 14, 24 In contrast to bi-allelic mutations, the phenotype associated with heterozygous rare variants is generally indistinguishable from that of idiopathic PD, and no distinctive features can be identified.
Psychiatric disturbances, in particular depression and anxiety, have been described in about one-third of PINK1 mutated patients regardless of onset age, often appearing early in the course of the disease and even before the manifestation of motor symptoms. 6, 11, 13, 15, [38] [39] [40] In a few PINK1 families, psychiatric symptoms were more severe and invalidating, and included major depression, dysphoria, obsessivecompulsive and psychotic traits, hallucinations, and other behavioural disturbances, which were occasionally reported also in some heterozygous relatives.
11,13,17,34,39-41 Cognitive impairment is rare, even after a prolonged disease course, and only a few patients have been described with progressive cognitive decline and dementia. 34, 40, 42 Although published data on olfactory function in PINK1 parkinsonism refer to only one patient with marked hyposmia, 8 in our series of cases olfactory function was found to be markedly impaired in all PINK1
homozygous and heterozygous patients, with defective identification and discrimination abilities but a more preserved threshold compared with idiopathic PD cases. Interestingly, olfactory defects were also detected in several asymptomatic carriers of PINK1 heterozygous mutations (unpublished data). 
Instrumental Diagnosis
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Functional neuroimaging studies in healthy heterozygous carriers also showed a mild but significant (20-30%) reduction of dopaminergic terminals, suggesting a role of heterozygous mutations in determining subclinical abnormalities in clinically asymptomatic subjects.
12,18,43
Transcranial ultrasonography of the substantia nigra in two homozygous and one heterozygous patient showed a hyperechogenic area significantly larger than in healthy controls although smaller than in idiopathic PD cases, in line with results observed in other monogenic forms of parkinsonism. 19 Moreover, a few studies assessed the myocardial (123) giving evidence that these types of PINK1 mutation are extremely rare and surely not able to account for the large proportion of heterozygous cases. This also applies for the other two mutational mechanisms that, although occasionally described in some genes, are overall rare.
Second, the second mutation could reside in a different gene, in a hypothetic model of digenic/oligogenic inheritance. This was suggested by occasional reports, such as a family with heterozygous mutations in both the PINK1 and DJ-1 genes, 49 and a sporadic patient compound heterozygous for PINK1 and Parkin mutations. 50 However, this hypothesis was excluded in several screenings that failed to identify concurrent mutations in other known ARP genes or LRRK2 in PINK1 heterozygotes.
